MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology, Inc. Frequently Asked Questions
What is the ticker symbol for MAIA Biotechnology, Inc.? What does MAIA stand for in stocks?
MAIA is the stock ticker symbol of MAIA Biotechnology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of MAIA Biotechnology, Inc. (MAIA)?
As of Fri Dec 20 2024, market cap of MAIA Biotechnology, Inc. is 52.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of MAIA stock?
You can check MAIA's fair value in chart for subscribers.
Is MAIA Biotechnology, Inc. a good stock to buy?
The fair value guage provides a quick view whether MAIA is over valued or under valued. Whether MAIA Biotechnology, Inc. is cheap or expensive depends on the assumptions which impact MAIA Biotechnology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MAIA.